Prognosis
India’s Covaxin Found 77.8% Effective in Lancet Covid Study
- Vaccine’s approval earlier this year in India prompted furor
- WHO granted emergency approval to Covaxin shot last week
This article is for subscribers only.
Covaxin, a vaccine developed by India’s medical research agency and Bharat Biotech International Ltd., was 77.8% effective at preventing symptomatic Covid-19 in an interim analysis of a long-awaited study.
Covaxin, which uses traditional, inactivated-virus technology, induced a robust antibody response two weeks after the second dose was given, the investigators concluded. No severe adverse events or vaccine-related deaths occurred during the randomized trial involving 24,419 adults. The research, conducted between November 2020 and May 2021 in India, was published in The Lancet.